# Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

> **NCT06950385** · PHASE3 · RECRUITING · sponsor: **Rapamycin Holdings Inc.** · enrollment: 168 (estimated)

## Conditions studied

- Familial Adenomatous Polyposis (FAP)

## Interventions

- **DRUG:** eRapa (encapsulated rapamycin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06950385
- **Lead sponsor:** Rapamycin Holdings Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2030-07
- **Final completion:** 2031-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06950385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06950385, "Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06950385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*